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Abstract
Background: Transcriptome analysis is emerging as emerging as a promising tool to enhance precision of
diagnosis and monitoring in solid organ transplantation. Clinical progress has however been hampered by the
current reliance on samples from core needle biopsies. This proof-of-principle study examined whether fine needle
aspirates, being less invasive, permit the ascertainment of the identical molecular information as core biopsies.
Methods: We collected fine needles aspirates from various needle sizes (G19, 21, 23, 25) and the corresponding
core biopsies (G16 needle) of non-tumor tissue of full nephrectomy specimens from patients suffering from clear
cell renal cell carcinoma (n = 11). RNA expression patterns of two gene sets (156 genes) were executed using
targeted RNA sequencing in samples from fine needle vs. core needle samples. A subgroup of kidneys (n = 6) also
underwent whole transcriptome RNA sequencing from core biopsies of tumor and peri-tumoral normal tissue (Tru
Seq RNA Access, Illumina).
Results: Samples from all needle sizes except two G25 aspirates yielded RNA potentially suitable for sequencing of
both gene sets. The mRNA expression patterns of the two gene sets were highly correlated between fine needle
aspirates (G23) and corresponding (G16) core biopsies (r = 0.985 and 0.982, respectively). This close correlation was
further documented by heat map, Principal Component Analyses (PCA) and whole transcription RNA sequencing.
The similarity between fine neddle aspirates and core needle biopsies was additionally confirmed in the subgroup
with complete RNA sequencing.
Conclusions: Fine needle biopsies yield similar genomic information to core needle biopsies. The less invasive
nature of fine needle biopsies may therefore permit more frequent molecular monitoring and a more targeted use
of core needle biopsies in native and especially in transplanted kidneys.
Keywords: Core biopsy, Fine needle aspiration, Gene expression, Rejection, RNA sequencing
Background
The diagnosis of rejection in renal transplantation is cur-
rently reliant on core needle biopsies given the lack of
specificity of renal function measurements in blood or
urine. Core biopsies are generally accepted to be safe but
are expensive, labor-intensive, and can be accompanied
by serious complications that may require hospitalization,
such as gross hematuria requiring blood transfusions as
well as even surgical interventions or angiographic embo-
lizations (1–2.5% of kidney biopsies) [1, 2]. Frequent mon-
itoring of transplanted kidney status using repeated core
needle biopsies is therefore not routinely feasible.
A less-invasive method of monitoring allograft status
would facilitate understanding and management of allo-
graft dysfunction. Such a tool would be especially rele-
vant where protocol biopsies are recommended to
detect subclinical T cell or antibody-mediated rejection,
prior to overt functional allograft deterioration, or where
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response to therapy may have been suboptimal in rou-
tine practice [3].
Molecular analyses are emerging as important tech-
niques to complement or in certain cases to even replace
tissue histology in diagnosis of transplant dysfunction.
Robust transcript sets have been identified which predict
future tissue alterations and/or reflect early acute or
chronic allograft rejection in renal allografts [4, 5]. A set
of 13 transcripts were found to be predictive of fibrosis
at 1 year and subsequent loss of allograft function [6].
Endothelial cell-derived transcript expression was shown
to reflect active antibody-mediated microvascular injury
and poor transplant outcome despite absence of histo-
logic C4d staining [7]. A gene set has been described
which differentiated polyomavirus-associated nephropa-
thy from acute renal allograft rejection [8]. In each of
these circumstances, the molecular diagnosis provided
relevant clinical information not revealed by histology
alone. Gene profiling has also been extended to other or-
gans and disease processes owing to the highly stereo-
typed and organ-unspecific molecular patterns associated
with inflammation and immune responses [9].
Given the inherent risk of repeated core needle biopsies,
but the high potential clinical value of obtaining transcrip-
tome information, we have investigated whether FNA, be-
ing less invasive, yields equivalent molecular information
to regular core needle biopsies. In this proof-of-principle
study we compared RNA sequencing results from two
well defined gene sets (cell cycle and Wnt panels) in aspi-
rates and biopsies from nephrectomy specimens.
Methods
Patients and tissue samples
Kidney tissue samples were obtained from patients (n =
11) with suspected renal cell carcinoma at the time of
radical nephrectomy. All patients had normal kidney
function (eGFR > 60 ml/min/1.73m2) and had under-
gone total nephrectomy. Key characteristics of the pa-
tients are outlined in Table 1. One 16 gauge (G16) core
biopsy and four fine needle aspirate samples (FNA)
using 19-, 21-, 23- and 25-gauge needles were obtained
with one pass (attempt) per individual biopsy or FNA
from normal appearing kidney tissue as far as possible
away from the tumor. Kidneys with warm ischemia time
over 2 hours were excluded. Ethics approval was granted
by the regional ethics committee of the Western Norway
Regional Health Authority (REK vest); approval number:
78–05. Written informed consent was obtained from all
patients.
Concurrently harvested kidney biopsies (G16) from
the tumor and adjacent normal tissue from a nested sub-
set (n = 6) of the total group of subjects (n = 11), stored
as formalin-fixed, paraffin-embedded (FFPE) tissues, had
previously been analyzed by whole transcriptome RNA
sequencing (TruSeq RNA Access kit®, Illumina, USA)
(Table 1) [10, 11]. The complete transcriptome RNA se-
quencing data from these patients (n = 6) were included
to investigate potential differences between whole tran-
scriptome and targeted sequencing.
RNA extraction and analysis
Core biopsy samples (G16) were immediately placed in
RNA later® (Qiagen, Netherlands). FNA samples (G19–
25) were placed directly into 700 μl of Qiazol lysis buffer
(Qiagen, Netherlands). Samples were stored at − 80 °C.
Core needle kidney biopsy samples were weighed and
cut into pieces of approximately 5 mg. Homogenization
of biopsy cores and FNA samples was performed in
700 μl Qiazol lysis buffer with ceramic beads. All sam-
ples were homogenized for 3 × 10 seconds at 6800 rpm
on a Precellys homogenizer (Bertin Technologies, USA).
Total RNA was extracted using the miRNeasy Micro kit
Table 1 Patient/sample overview at the time of nephrectomy (n = 11)
Patient Targeted-panel seq Core biopsy
(G16) [healthy tissue]
Targeted-panel seq FNA
(G23) [healthy tissue]
Whole transcriptome RNAseq (G16),
Tumor [tumor biopsy]
Whole transcriptome RNAseq (G16), Non
tumor [healthy tissue]
39 N X X X X
42 N X X
44 N X X X X
47 N X X
49 N X X
50 N X X X X
57 N X X X X
64 N X X X X
65 N X X X X
66 N X X
69 N X X
Seven males and four females with a mean age of 64 years (95% CI: 58–70) were included. A subset of patients (n = 6) underwent both two-panel mRNA
sequencing and full mRNA sequencing
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(Qiagen, Netherlands). RNA was stored at -80C until
further use for RNA sequencing.
RNA concentration was measured using a NanoDrop
1000 spectrophotometer (Thermo Fisher Scientific, USA).
RNA integrity was assessed using the Agilent RNA 6000
Nano kit on a 2100 Bioanalyzer (Agilent Technologies,
USA). The DV200 value (the percentage of RNA frag-
ments longer than 200 nucleotides) was used to reflect
RNA quality for subsequent sequencing from FFPE tissues
[10, 11]. A minimum DV200 value of 30% is recom-
mended and required for RNA sequencing [12]. RNA in-
tegrity number (RIN) values were also determined.
RNA sequencing
RNA sequencing and analyses were conducted using tar-
geted RNA expression, heatmaps and PCA. RNA se-
quencing was performed using two different predesigned
TruSeq Targeted RNA panels from Illumina©. Panel se-
quencing was selected because, if successful, sequencing
of defined gene panels (e.g. related to rejection pro-
cesses) is much more likely to be integrated into routine
clinical practice than full transcriptome sequencing.
To test the potential utility of FNA-derived RNA se-
quencing, gene sets with relevance in kidney allografts
were selected. The TruSeq Targeted RNA Expression “Cell
Cycle Panel” includes 63 genes/transcripts participating in
the cell cycle and DNA replication. The complete gene set
of this expression panel is available at http://www.suppor-
t.illumina.com/content/illumina-marketing/en/products/
truseq-targeted-rna-expressioncell-cycle-panel.html. This
panel was selected because cell cycle genes would reflect
injury-repair mechanisms in the renal allograft [13]. The
TruSeq Targeted RNA Expression “Wnt Panel” includes
assays for 93 genes/transcripts involved in upstream and
downstream signal transduction in the Wnt signalling
pathway, including transcription factors as well as target
genes. The complete gene list of this expression panel is
available at http://www.support.illumina.com/content/illu-
mina-marketing/en/products/truseq-targeted-rna-expres-
sionwnt-panel.html. This panel was selected given its
general importance in biological processes, and because
the wnt pathway has been implicated in chronic renal allo-
graft injury [14].
Sequencing libraries were generated according to
manufacturer’s instructions (Illumina, Inc., San Diego,
USA) with RNA normalized to inputs of 200 ng total
RNA from each sample. Equal amounts of libraries
were pooled (normalized) to a final concentration of 18
pM and subjected to cluster and single end read
sequencing.
Sequencing was performed for 50 cycles using MiSeq
Reagent Kit v3 on a MiSeq® instrument (Illumina, Inc.,
San Diego, USA). Base calling was done on the instru-
ment and Fastq files were generated using bcl2fastq
v.2.18 with default settings for the RNA-seq data. Tran-
script expression values were determined using the Sal-
mon software [15] with the GRCh37 transcriptome
downloaded from the Ensembl database (http://www.en-
sembl.org/).
Gene counts from the 2 gene sets were combined in
the tximport package (https://bioconductor.org/pack-
ages/release/bioc/html/tximport.html). Genes with less
than two counts total were filtered out prior to analysis.
Variance transformed expression data was generated
with the DESeq2 package (https://bioconductor.org/
packages/release/bioc/html/DESeq2.html) using the rlog
transform on count data. Heatmaps for expression data
were generated using the pheatmap package (https://
cran.r-project.org/web/packages/pheatmap) and hier-
archical clustering of genes and samples in the heatmap
was generated using the Ward’s clustering method and
correlation distances. Principal Component Analysis
(PCA) was performed on variance transformed data
(rlog) and visualized using the ggfortify package (https://
cran.r-project.org/web/packages/ggfortify). The average
expression values for the G16 biopsy (n = 11) and G23
FNA (n = 11) gene panel data, as well as for the prior
G16 biopsy (n = 6) whole transcriptome data, were en-
tered into a generalized pair plot using the GGally pack-
age (https://cran.r-project.org/web/packages/GGally).
The datasets created during and/or analysed during
the current study are available from the corresponding
author upon reasonable request.
Results
RNA quantity and quality obtained from fine needle
aspirates (FNA) and core needle biopsies is sufficient and
high
A subset of nephrectomy samples (n = 6) underwent
both, prior sequencing of whole transcriptome RNA (as
recently published [11]) and sequencing of two targeted
RNA expression panels from core biopsies and FNAs.
The results from the whole transcriptome RNA sequen-
cing (n = 6) served as an internal control and compara-
tor (n = 6) to detect differences between whole
transcriptome and targeted panel sequencing.
RNA quality for sequencing was expressed by the RIN
and the DV200 values. The quantity (Fig. 1a) and quality
(Fig. 1b and c) of extracted RNA from the 11 samples
stratified by different needle sizes is shown in Fig. 1.
The mean DV200 values (95% CI) were 56% (43–69)
for G23 FNA samples and 68% (62–74) for G16 core bi-
opsy samples. The DV200 percentages well exceed the
30% minimum required for RNA sequencing [12]. The
RIN-values were 3.3 (1.7–4.8) and 5.1 (3.2–6.9) for the
FNA samples and G16 biopsies, respectively. Import-
antly, RIN-values and DV200 numbers were not signifi-
cantly different between any of the needle sizes
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(G16-G25), as assessed by one-way ANOVA with Tukey’s
multiple comparisons test (Fig. 1); adj. p ≥ 0.13 for all
comparisons.
These RIN values reflected the expected RNA degradation
from our FFPE tissues. However, RIN values derived from
FFPE samples are not a reliable predictor of RNA quality or
of successful library preparation using the Illumina TruSeq
RNA Access Kit®, as investigated by the vendor, https://
www.illumina.com/documents/products/technotes/technote-
trusec-rna-access.pdf and recently described [10]. Mean
RNA fragment sizes reflected by the DV200 percentages and
not RIN values were therefore used to asses RNA quality
from FFPE tissues for the subsequent RNA sequencing li-
brary preparation [10, 12, 16, 17].
As expected, one-way ANOVA with Tukey’s multiple
comparisons test revealed a significantly lower RNA
yield from all FNA compared to G16 core biopsy sam-
ples (Fig. 1). However, there were no significant differ-
ences in the RNA yield between any of the fine needle
aspirates (G19-G25); adj. p ≥ 0.11 for all comparisons.
FNA from needles of all tested sizes consistently yielded
sufficient quantities of RNA for sequencing with the ex-
ception of two G25 aspirates, which would have permitted
sequencing of only one gene panel. Also, the total RNA
yield from some of these G25 size aspirations was, how-
ever, at the threshold of 50 ng/sample required for RNA
input for both sequencing panels according to Illumina
(http://www.support.illumina.com/content/illumina-market
ing/en/products/truseq-targeted-rna-expressionwnt-panel.
html and http://www.support.illumina.com/content/
illumina-marketing/en/products/truseq-targeted-rna-expres
sion-cell-cycle-panel.html). RNA sequencing analyses
were therefore performed using the G23 FNA
aspirates, as the yield was reliable and this needle size
is routine used for FNA in clinical practice.
High degree of similarity in gene expression as depicted
in a heatmap
The heatmap (Fig. 2) depicts the transcript levels of the
total of 156 genes included in both panels (cell cycle and
Wnt pathway). Overall the gene expression pattern ob-
tained by RNA sequencing shows a high degree of simi-
larity between the 11 FNA (G23) and the corresponding
11 core needle biopsy samples (G16); samples of some
patients (e.g. 50 N) clustered together closely, others did
not.
Principal component analyses detecting similarity and
dissimilarity among the datasets
The Principal Component Analysis (PCA) describes the
variance across the four groups (Table 1). Figure 3a de-
picts a clear separation between i) the two sample sets
analyzed with targeted RNA sequencing (G23, n = 11;
and G16, n = 11), and ii) the two sample sets from the
subset of patients with additional complete RNA se-
quencing of renal cell carcinoma tissues (“Tumor”, n =
6) and their adjacent renal tissue (“Non tumor”, n = 6).
The two components (PC1 and PC2) of the PCA indi-
cate that the expression patterns of the whole-genome
based tumor tissues differs from non-tumor tissues, but
taken together these two whole genome groups are
much more dissimilar to the targeted sequencing sam-
ples. Therefore, the internal comparator group with
complete RNA sequencing underscores the similarity
Fig. 1 RNA yield and RNA quality of FNA samples (G19-G25) and of
corresponding core biopsy samples (G16). a. RNA yield (ng/sample)
was higher in G16 biopsies compared to all FNA (G19–25) samples
(***p = 0,0003; ****p < 0,0001). b. RNA quality by RIN values, and c.
RNA quality by DV200 values
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between fine (G23) and core needle biopsies (G16) with
targeted sequencing. The FNA (G23) and core biopsy
(G16) groups show a high degree of overlap, indicating
similar expression patterns in the sequencing results of
the two gene panels.
The validity of RNA sequencing obtained from FNA
samples is further underlined by the PCA in Fig. 3b,
which emphasizes the lack of dissimilarity in RNA ex-
pression between the G23 and G16 samples, with low
variance across the two dimensions PC1 and PC2. RNA
expression in FNA and core needle biopsies therefore
overlap closely.
Significant correlation in gene expression between fine
needle and core needle biopsies
To test the true utility of FNA against current standard
core biopsy samples, we analyzed the correlation of gene
expression between the two gene panels measured by se-
quencing in each of the three different sample groups:
11 FNA samples (G23), 11 core needle biopsies (G16)
and 6 non-tumor whole genome tissue samples.
Figure 4 shows the high correlation for the mRNA ex-
pression patterns of the “cell cycle” (n = 63) and “Wnt”
panel (n = 93) genes between the FNA and the respect-
ive core biopsies (r = 0.982 for all genes, 0.985 for cell
cycle, and 0.982 for WNT panel, resp.). A minority of
genes (n = 28) from the total of 156 genes were differen-
tially expressed between the G23 and G16 groups, in-
cluding genes such as MMP-9, MMP-2, IL-6, and
FOXN1 which play a role in inflammatory or immuno-
logic processes (data not shown); this variability could
be explained by the respective G23 and G16 needle loca-
tion. The correlation of mRNA expression patterns be-
tween G23 and G16 samples and the respective results
of the fully sequenced group (“Non tumor”, n = 6) was
lower (r values between 0.791 and 0.923).
Discussion
This study demonstrates that RNA sequencing of FNA
samples provides equivalent molecular information to
that of core needle biopsy samples. These proof of
principle findings may justify a less invasive approach to
Fig. 2 Heatmap. Hierarchical clustering of genes and samples generated using the Ward’s clustering method and correlation distances between
samples and Euclidean distances between genes. The heatmap cells are colored proportional to rlog expression values
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immune monitoring in organ transplantation, which
thus far has heavily relied on full core biopsies.
Currently percutaneous FNA is often performed for
cancer diagnosis in various solid organs, such as breast,
liver, and thyroid gland as well as in accessible lymph
nodes [18]. FNAs are much easier to perform than core
needle biopsies and are associated with significantly
fewer complications. A recent metaanalysis of more than
4500 patients undergoing core-needle biopsy and/or
FNA for thyroid cancer diagnosis reported an essentially
0 % complication rate [18]. In addition, cessation of oral
anticoagulation or anti-platelet agents might not be ne-
cessary before fine needle aspiration [19, 20]. Import-
antly also, patients with potentially malignant renal
masses, who have many comorbidities (e.g. cardiac
events necessitating stents and platelet inhibitors) and a
high operative risk, could benefit from the less invasive
initial fine needle approach that includes transcriptome
analyses. Indeed, a recent study demonstrated very good
diagnostic accuracy - and a synergistic diagnostic advan-
tage - of both FNA and core needle biopsy for renal
masses in native kidneys [21]. Similar evidence in renal
transplantation is lacking.
The present study demonstrates that sufficient
quantities of RNA suitable for RNA sequencing can
be obtained with a wide variety of fine needle sizes.
Moreover, the comparative analyses indicate excellent
correlation of mRNA expression patterns abundances
obtained by FNA and full core biopsies. The internal
comparator group with complete RNA sequencing fur-
ther highlighted the similarity between fine and core nee-
dle biopsies with targeted sequencing.
This study has several important strengths. Current
FNA and core biopsy samples were obtained under
direct vision after nephrectomy and permitting strin-
gent comparability of RNA expression from the vari-
ous procedures taken from the same tissue area. The
quality and quantity of RNA obtained by FNA was
robust and therefore strongly suggest that FNA may
be a viable diagnostic tool in selected patients. Des-
pite these encouraging findings however, our study
has several limitations that must be acknowledged.
Samples were obtained from explanted kidneys which
were no longer perfused, therefore potential con-
founding of FNA reproducibility by circulating blood
cells as compared with core biopsy samples cannot be
addressed. Comparative studies in perfused organs are
required to assess the influence of peripheral blood
and biopsy/aspiration site on the results. Clinical
complications could not be assessed in this study,
A B
Fig. 3 Principal Component Analyses (PCA). The first two principal components from a Principal Component Analysis using rlog transformed
expression values. a. Principal Component Analysis (PCA) of samples from all four groups described in Table 1. The first principal component (PC1,
x-axis) explains 47% of the variation in the data while the second principal component (PC2, y-axis) increases total explained variation to 56%.
Confidence ellipsis at 99% is drawn for each group. b. Principal component analysis (PCA) of G23 vs. G16. The first principal component (PC1, x-
axis) explains 16% of the variation in the data while the second principal component (PC2, y-axis) increases total explained variation to 30%.
Confidence ellipsis at 99% is drawn for each group
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however a proof-of-principal study such as ours is a
necessary ethical pre-requisite prior to consideration
of clinical studies. Further limitations to our study in-
clude the facts that we provide panel sequencing and
not complete RNA sequencing of the whole genome
and that we did not determine the variability of RNA
expression between multiple FNA aspirates and the
same biopsy. Moreover, FNA is not able to deliver
the transcriptome of individual cell types and a de-
tailed pathology report cannot be assigned to an
FNA. In addition, as with all transcriptome studies, it
remains to be shown if mRNA results of our selected
panel genes can be extrapolated to the respective
gene product on the protein level and to other genes
and pathways.
Transcriptome analysis has not yet reached the clinical
mainstream and therefore the true clinical impact of fa-
cilitated transcriptome/RNA monitoring also requires
prospective studies. It could be argued that the current
hesitation in performing multiple biopsies in the same
Fig. 4 Correlations of gene expression. The x- and y-axis in each scatterplot represent average rlog transformed expression values for G16, G23
and non-tumor samples. The individual points are colored by the gene panel origin. The diagonal plots are density curves for the individual
points and Pearson correlations are given for all genes (Cor; black), the WNT genes (WNT; green) and the Cell cycle genes (CC; magenta)
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patient may have hindered progress in understanding
the clinical value of the transcriptome. The use of FNA
may therefore accelerate understanding of its clinical
relevance. The close correlation of gene expression from
RNA obtained with FNA as compared with core biop-
sies, as well as the relative safety, justifies further investi-
gation and confirmation of the value of FNA in
prospective clinical studies.
It is important to acknowledge however that FNA is
not an adequate source for histological investigations.
Therefore, we do not suggest that FNA can replace all
histologic analysis, which remains important for diagno-
sis of disease recurrence, borderline rejection changes,
viral infections etc. We continue to support the need for
histology especially for the first biopsy to ensure that un-
expected and transplant-unrelated diagnoses are not
missed. It is conceivable however that FNA could re-
place protocol biopsies, especially where allograft func-
tion appears normal. More frequent monitoring with
serial protocol FNA in immunologically high-risk kidney
allografts might detect rejection processes earlier than
histological changes and/or an overt decline in kidney
function. Candidate gene panels for transplant rejection
have already been defined [22, 23]. FNA would also be
an attractive procedure for follow up monitoring of tis-
sue response to therapy after a core biopsy baseline
histologic and transcriptome diagnosis is made. Avail-
ability of diagnosis using FNA could optimize timing
and reduce frequency of indication of core needle biop-
sies not only in kidney but also in other transplanted
organs.
Conclusions
In conclusion, fine needles aspirates reproducibly reflect
molecular information in the kidney. FNA may therefore
provide a simple and safe tool to monitor native and es-
pecially transplanted kidneys by supplementing the more
invasive core needle biopsies and could provide access-
ible information to guide clinical decision making.
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